ny-eso-1(c259)t cells
Cell therapyexperimental
Clinical trial activity
3 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Mar 1, 2011 (NCT01343043)
Timeline
2010s
- Jan 1, 2011
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Cancer/testis antigen 1Immunity, passive
Cancer/testis antigen 1 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- ny-eso-1(c259)t cells
- ny-eso-1c259 t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03168438 | Early Phase 1 (Phase 1) | May 24, 2017 | Adaptimmune, GlaxoSmithKline, Merck, University of South Florida |
| NCT01567891 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2013 | Adaptimmune, State University of New York, Buffalo |
| NCT01343043 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2011 | Adaptimmune, Cornell University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Adaptimmune | For profit | 3 | 3 | 2 | 2011 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| GlaxoSmithKline | For profit | 1 | 0 | 1 | 2017 |
| Merck | For profit | 1 | 0 | 1 | 2017 |
| State University of New York, Buffalo | Academic/Hospital | 1 | 0 | 1 | 2013 |
| University of South Florida | Academic/Hospital | 1 | 0 | 1 | 2017 |
6 organizations
Page 1 / 1